Supernus Pharmaceuticals (SUPN) Goodwill & Intangibles (2016 - 2025)
Supernus Pharmaceuticals (SUPN) has disclosed Goodwill & Intangibles for 15 consecutive years, with $502.1 million as the latest value for Q1 2025.
- On a quarterly basis, Goodwill & Intangibles fell 13.39% to $502.1 million in Q1 2025 year-over-year; TTM through Mar 2025 was $502.1 million, a 13.39% decrease, with the full-year FY2024 number at $521.9 million, up 346.01% from a year prior.
- Goodwill & Intangibles was $502.1 million for Q1 2025 at Supernus Pharmaceuticals, down from $521.9 million in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $784.7 million in Q4 2021 to a low of $117.0 million in Q4 2023.
- A 5-year average of $508.5 million and a median of $550.8 million in 2024 define the central range for Goodwill & Intangibles.
- Peak YoY movement for Goodwill & Intangibles: plummeted 83.34% in 2023, then skyrocketed 346.01% in 2024.
- Supernus Pharmaceuticals' Goodwill & Intangibles stood at $784.7 million in 2021, then fell by 10.48% to $702.5 million in 2022, then tumbled by 83.34% to $117.0 million in 2023, then surged by 346.01% to $521.9 million in 2024, then dropped by 3.79% to $502.1 million in 2025.
- Per Business Quant, the three most recent readings for SUPN's Goodwill & Intangibles are $502.1 million (Q1 2025), $521.9 million (Q4 2024), and $117.0 million (Q3 2024).